Tocilizumab (Actemra®)

Phase 2

Roche Holding AG (RHHBY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

RHHBYPhase 2$351.3B

Tocilizumab (Actemra®) Phase 2 Est. Readout

Tocilizumab (Actemra®)• Acute Hypoxemic Respiratory Failure60

Feb 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Acute Hypoxemic Respiratory Failure

View Full Landscape

Drug Information

Target Indication

Acute Hypoxemic Respiratory Failure

Clinical Trial

NCT07334379

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

MabTheraPhase 3

Humoral Rejection in Kidney Transplantation

RO7239361Phase 3

Duchenne Muscular Dystrophy

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts